| Literature DB >> 35096569 |
Chunwang Huang1,2, Wenxiao Yan1, Shumei Zhang3, Yanping Wu1, Hantao Guo1, Kunming Liang4, Wuzheng Xia5, Shuzhen Cong1,2.
Abstract
BACKGROUND: Given the difficulty of accurately determining the central lymph node metastasis (CLNM) status of patients with clinically node-negative (cN0) papillary thyroid carcinoma (PTC) before surgery, this study aims to combine real-time elastography (RTE) and conventional ultrasound (US) features with clinical features. The information is combined to construct and verify the nomogram to foresee the risk of CLNM in patients with cN0 PTC and to develop a network-based nomogram.Entities:
Keywords: central lymph node metastasis (CLNM); clinically node-negative; nomogram; papillary thyroid carcinoma; real-time elastography (RTE); ultrasonography
Year: 2022 PMID: 35096569 PMCID: PMC8792045 DOI: 10.3389/fonc.2021.755273
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Flowchart of enrolled cN0 papillary thyroid carcinoma patients.
Clinical and US features of cN0 PTC in the development and validation cohorts.
| Characteristic | Development cohort ( | Validation cohort ( | ||||
|---|---|---|---|---|---|---|
| CLNM(−) ( | CLNM(+) ( |
| CLNM(−) ( | CLNM(+) ( |
| |
| Age (mean ± SD, range, years) | 44.95 ± 9.49 (18–73) | 41.01 ± 9.47 (14–73) | <0.001 | 43.40 ± 9.51 (19–70) | 39.03 ± 9.45 (23–68) | <0.001 |
| Sex ( | ||||||
| Female | 327 (81.5) | 257 (69.5) | <0.001 | 165 (77.8) | 120 (69.0) | 0.049 |
| Male | 74 (18.5) | 113 (30.5) | 47 (22.2) | 54 (31.0) | ||
| Tumor size (cm) | 1.01 ± 0.50 (0.3–6.4) | 1.37 ± 0.52 (0.3–7) | <0.001 | 0.99 ± 0.49 (0.3–6.3) | 1.28 ± 0.50 (0.3–6.9) | <0.001 |
| Tumor position ( | ||||||
| Left lobe | 172 (42.9) | 146 (39.4) | 0.039 | 94 (44.3) | 71 (40.8) | 0.025 |
| Right lobe | 218 (54.4) | 200 (54.1) | 116 (54.7) | 93 (53.4) | ||
| Isthmus and conical lobe | 11 (2.7) | 24 (6.5) | 2 (1.0) | 10 (5.8) | ||
| Multifocality ( | ||||||
| No | 328 (81.8) | 268 (72.4) | 0.002 | 183 (86.3) | 121 (69.5) | <0.001 |
| Yes | 73 (18.2) | 102 (27.6) | 29 (13.7) | 53 (30.5) | ||
| Bilateral tumors ( | ||||||
| No | 358 (89.3) | 286 (77.3) | <0.001 | 191 (90.1) | 134 (77.0) | <0.001 |
| Yes | 43 (10.7) | 84 (22.7) | 21 (9.9) | 40 (23.0) | ||
| Very hypoechoic/hypoechoic ( | ||||||
| No | 47 (11.7) | 44 (11.9) | 0.941 | 30 (14.2) | 26 (14.9) | 0.826 |
| Yes | 354 (88.3) | 326 (88.1) | 182 (85.8) | 148 (85.1) | ||
| Calcification ( | ||||||
| 0 | 128 (31.9) | 62 (16.8) | <0.001 | 68 (32.1) | 31 (17.8) | 0.003 |
| 1 | 250 (62.3) | 292 (78.9) | 133 (62.7) | 137 (78.7) | ||
| 2 | 23 (5.8) | 16 (4.3) | 11 (5.2) | 6 (3.5) | ||
| NCS ( | ||||||
| 0 | 208 (51.9) | 124 (33.5) | <0.001 | 126 (59.4) | 61 (35.1) | <0.001 |
| 1 | 161 (40.1) | 159 (43.0) | 69 (32.6) | 74 (42.5) | ||
| ≥2 | 32 (8.0) | 87 (23.5) | 17 (8.0) | 39 (22.4) | ||
| Composition ( | ||||||
| Cystic | 2 (0.5) | 2 (0.5) | 0.936 | 2 (0.9) | 1 (0.6) | 0.681 |
| Solid | 399 (99.5) | 368 (99.5) | 210 (99.1) | 173 (99.4) | ||
| Shape ( | ||||||
| Regular | 14 (3.5) | 13 (3.5) | 0.987 | 12 (5.7) | 5 (2.9) | 0.184 |
| Irregular | 387 (96.5) | 357 (96.5) | 200 (94.3) | 169 (97.1) | ||
| Taller than wide ( | ||||||
| ≤1 | 110 (27.4) | 144 (38.9) | <0.001 | 57 (26.9) | 62 (35.6) | 0.064 |
| >1 | 291 (72.6) | 226 (61.1) | 155 (73.1) | 112 (64.4) | ||
| Margin ( | ||||||
| Well-defined | 19 (4.7) | 15 (4.1) | 0.644 | 8 (3.8) | 9 (5.2) | 0.505 |
| Ill-defined | 382 (95.3) | 355 (95.9) | 204 (96.2) | 165 (94.8) | ||
| CLT ( | ||||||
| Absence | 253 (63.1) | 271 (73.2) | 0.003 | 140 (66.0) | 112 (64.4) | 0.732 |
| Presence | 148 (36.9) | 99 (26.8) | 72 (34.0) | 62 (35.6) | ||
| Internal vascularity ( | ||||||
| 0 | 58 (14.5) | 27 (7.3) | <0.001 | 35 (16.5) | 13 (7.5) | <0.001 |
| 1 | 186 (46.4) | 139 (37.6) | 100 (47.2) | 69 (39.7) | ||
| 2 | 74 (18.4) | 90 (24.3) | 35 (16.5) | 54 (31.0) | ||
| 3 | 83 (20.7) | 114 (30.8) | 42 (19.8) | 38 (21.8) | ||
| RTE ( | ||||||
| 0 | 57 (14.2) | 14 (3.8) | <0.001 | 27 (12.7) | 6 (3.4) | <0.001 |
| 1 | 316 (78.8) | 231 (62.4) | 172 (81.1) | 103 (59.2) | ||
| 2 | 28 (7.0) | 125 (33.8) | 13 (6.2) | 65 (37.4) | ||
NCS, number of contact surface; CLT, chronic lymphocytic thyroiditis; RTE, real-time elastography.
Risk factors and regression coefficient of prediction models.
| Intercept and variable | Model 1 | Model 2 | ||||
|---|---|---|---|---|---|---|
| Coefficient | OR (95% CI) |
| Coefficient | OR (95% CI) |
| |
| Intercept | −0.808 | 0.446 (0.175, 1.093) | 0.083 | 0.224 | 1.251 (0.628, 2.496) | 0.524 |
| Sex | ||||||
| Female | 1 (reference) | 1 (reference) | ||||
| Male | 0.621 | 1.861 (1.264, 2.752) | 0.002 | 0.665 | 1.944 (1.354, 2.802) | <0.001 |
| Age | −0.034 | 0.967 (0.953, 0.981) | <0.001 | −0.033 | 0.968 (0.955, 0.981) | <0.001 |
| Tumor size | 0.504 | 1.655 (1.258, 2.21) | <0.001 | 0.5 | 1.648 (1.261, 2.183) | <0.001 |
| Bilateral tumors | ||||||
| No | 1 (reference) | 1 (reference) | ||||
| Yes | 0.859 | 2.362 (1.508, 3.738) | <0.001 | 0.786 | 2.194 (1.435, 3.388) | <0.001 |
| NCS | ||||||
| 0 | 1 (reference) | 1 (reference) | ||||
| 1 | 0.575 | 1.777 (1.244, 2.548) | 0.002 | 0.504 | 1.655 (1.189, 2.31) | 0.003 |
| 2 | 1.148 | 3.153 (1.815, 5.556) | <0.001 | 1.152 | 3.164 (1.867, 5.438) | <0.001 |
| CLT | ||||||
| Absence | 1 (reference) | 1 (reference) | ||||
| Presence | −0.484 | 0.617 (0.43, 0.879) | 0.008 | −0.466 | 0.628 (0.449, 0.873) | 0.006 |
| RTE | NA | NA | NA | |||
| 0 | 1 (reference) | |||||
| 1 | 0.743 | 2.101 (1.119, 4.199) | 0.027 | |||
| 2 | 2.715 | 15.111 (7.263, 33.366) | <0.001 | |||
OR, odds ratio; NCS, number of contact surface; CLT, chronic lymphocytic thyroiditis; RTE, real-time elastography; NA, not applicable.
Figure 2ROC curves of the two models in the training dataset.
Figure 3ROC curves of the two models in the validation dataset.
Figure 4The nomogram of model 1 for predicting the risk of CLNM in cN0 PTC.
Figure 5Calibration curves of the prediction model 1 in the development and validation cohorts.
Performance of the prediction model for assessing the risk of CLNM.
| Variable | Value (95% CI) | ||
|---|---|---|---|
| Development cohort ( | Validation cohort (386) | Combined cohorts ( | |
| AUC | 0.798 (0.768, 0.829) | 0.792 (0.746, 0.837) | 0.796 (0.771, 0.821) |
| Cutoff value | 0.407 | 0.407 | 0.407 |
| Sensitivity (%) | 76.49 (71.83, 80.72) | 77.59 (70.66, 83.55) | 76.84 (73.06, 80.32) |
| Specificity (%) | 69.58 (64.82, 74.04) | 66.51 (59.72, 72.83) | 68.52 (64.67, 72.18) |
| PPV (%) | 69.88 (65.15, 74.31) | 65.53 (58.61,72) | 68.41 (64.56, 72.08) |
| NPV (%) | 76.23 (71.53, 80.5) | 78.33 (71.59, 84.12) | 76.92 (73.16, 80.39) |
| Positive likelihood ratio | 2.51 (2.15, 2.95) | 2.32 (1.89, 2.85) | 2.44 (2.15, 2.77) |
| Negative likelihood ratio | 0.34 (0.28, 0.41) | 0.34 (0.25, 0.45) | 0.34 (0.29, 0.4) |
| Diagnosed accuracy (%) | 72.89 (69.61, 76) | 71.50 (66.72, 75.96) | 72.43 (69.76, 74.99) |
PPV, positive predictive value; NPV, negative predictive value.
Figure 6Decision curve analysis of prediction model 1.
Figure 7Screen shot of the dynamic US-based nomogram used to predict central lymph node metastasis in cN0 papillary thyroid carcinoma (https://predictclnminptc.shinyapps.io/DynNomapp/).